3Morton LM, Wang SS, Devesa SS, et al.Lymphoma incidence patterns by WHO subtype in the United States, 1992 -2001 [J]. Blood,2006,107 ( 1 ) :265 -276.
4Saidel H, Nygaard R, Moe PJ, et al. On the prognostic value of systemic methotrexate clearance in childhood acute lymphoblastic leukaemia [J]. Leuk Res,1997,21(5):429-434.
6Aumente D, Buelga DS, Lukas JC, et al.Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastie leukaemia [J]. Chn Pharmacokinet, 2006,45(12):1227-1238.
7Kanbayashi Y1, Nomura K, Okamoto K,et al. Statistical examination to determine whether only 48-h value for serum concentration during high-dose methotrexate therapy is a predictor for clinical adverse events using ordered logistic regression analysis [J].Ann Hematol, 2010,89(10): 965-969.
10Skarby TV, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastie leukemia [J]. Leukemia,2006,20( 11 ): 1955-1962.
1Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma [ J ]. Cancer, 2010, 116 ( 18 ) : 4283- 4290. DOI: 10.1002/ener.25278.
